RNAZTransCode Therapeutics, Inc.

RNAZ Stock Price, Valuation & Chart | TransCode Therapeutics, Inc.

Compare

$2.010-0.05 (-2.43%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology RNAZ intrinsic value RNAZ calculated fair value vs price

Overview Financials Dividends Ratios

RNAZ Historical price chart

RNAZ Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.13M

PE Ratio-0.04

EPS-52.52

Trading Volume22.32K

Today's High/Low2.1/2.01

Dividend Yield0.00

52 Week High/Low20.99/1.83

Shares Outstanding1.06M

RNAZ Financial Statement

RNAZ Analyst ratings

RNAZ Analysis & performance metrics

RNAZ Company profile

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic…

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator…

RNAZ Management team

Name

Position

Thomas A. Fitzgerald M.B.A.CEO

Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration & Director

Philippe P. Calais Ph.D., Pharm., Pharm.D.

Executive Chairman of the Board

Susan Duggan M.B.A., R.N.

Senior Vice President of Operations

Zdravka Medarova Ph.D.

Co-Founder & Chief Scientific Officer

Anna Moore Ph.D.

Co-Founder, Scientific Advisor & Member of Scientific Advisory Board

Daniel R. Vlock M.D.

Chief Medical Officer

Name

Position

Thomas A. Fitzgerald M.B.A.CEO

Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration & Director

Philippe P. Calais Ph.D., Pharm., Pharm.D.

Executive Chairman of the Board

Susan Duggan M.B.A., R.N.

Senior Vice President of Operations

Zdravka Medarova Ph.D.

Co-Founder & Chief Scientific Officer

Anna Moore Ph.D.

Co-Founder, Scientific Advisor & Member of Scientific Advisory Board

Daniel R. Vlock M.D.

Chief Medical Officer

Management Team

Thomas A. Fitzgerald M.B.A.CEO

Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration & Director

Philippe P. Calais Ph.D., Pharm., Pharm.D.

Executive Chairman of the Board

Susan Duggan M.B.A., R.N.

Senior Vice President of Operations

Zdravka Medarova Ph.D.

Co-Founder & Chief Scientific Officer

Anna Moore Ph.D.

Co-Founder, Scientific Advisor & Member of Scientific Advisory Board

Daniel R. Vlock M.D.

Chief Medical Officer

Management

Thomas A. Fitzgerald M.B.A.CEO

Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration & Director

Philippe P. Calais Ph.D., Pharm., Pharm.D.

Executive Chairman of the Board

Susan Duggan M.B.A., R.N.

Senior Vice President of Operations

Zdravka Medarova Ph.D.

Co-Founder & Chief Scientific Officer

Anna Moore Ph.D.

Co-Founder, Scientific Advisor & Member of Scientific Advisory Board

Daniel R. Vlock M.D.

Chief Medical Officer

Total 6 executives

RNAZ Frequently asked questions

What is TransCode Therapeutics, Inc. (RNAZ) Stock Price?

Current stock price of TransCode Therapeutics, Inc. (RNAZ) stock is $2.010. The stock price is -2.43% lower in the session. The intraday range can be seen from this page. Volume of TransCode Therapeutics, Inc. (RNAZ) stock is 22.32K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the TransCode Therapeutics, Inc. (RNAZ) stock price going up or down today?

The stock price of TransCode Therapeutics, Inc. (RNAZ) can change with earnings, company news, and overall market sentiment. TransCode Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the TransCode Therapeutics, Inc. stock expensive at its current price?

Whether TransCode Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for RNAZ on this page is -0.04. EPS on this page is -52.52. Compare those figures with peers and growth expectations before deciding if the current TransCode Therapeutics, Inc. price is justified.

How has the stock price of TransCode Therapeutics, Inc. (RNAZ) performed historically?

Historical performance for TransCode Therapeutics, Inc. (RNAZ) is shown on the price chart on this page. Review multi-period moves alongside volume to see how RNAZ reacted to past earnings and market events.

Should I buy TransCode Therapeutics, Inc. (RNAZ) stock, at this price?

Buying TransCode Therapeutics, Inc. (RNAZ) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.